221 related articles for article (PubMed ID: 35622315)
1. Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis: 52-Week Results.
Okubo Y; Umezawa Y; Sakurai S; Hoshii N; Nakagawa H
Dermatol Ther (Heidelb); 2022 Jun; 12(6):1397-1415. PubMed ID: 35622315
[TBL] [Abstract][Full Text] [Related]
2. Ixekizumab 80 mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis.
Morita A; Okubo Y; Morisaki Y; Torisu-Itakura H; Umezawa Y
Dermatol Ther (Heidelb); 2022 Feb; 12(2):481-494. PubMed ID: 34967916
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results.
Umezawa Y; Asahina A; Imafuku S; Tada Y; Sano S; Morita A; Sakurai S; Hoshii N; Tilt N; Nakagawa H
Dermatol Ther (Heidelb); 2021 Jun; 11(3):943-960. PubMed ID: 33886085
[TBL] [Abstract][Full Text] [Related]
4. Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study.
Umezawa Y; Sakurai S; Hoshii N; Nakagawa H;
Dermatol Ther (Heidelb); 2021 Apr; 11(2):513-528. PubMed ID: 33606269
[TBL] [Abstract][Full Text] [Related]
5. Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy.
Imafuku S; Tada Y; Umezawa Y; Sakurai S; Hoshii N; Nakagawa H
Dermatol Ther (Heidelb); 2022 Jan; 12(1):121-135. PubMed ID: 34826124
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: Primary analysis and 180-week follow-up results from the phase 3, multicenter IMMspire study.
Yamanaka K; Okubo Y; Yasuda I; Saito N; Messina I; Morita A
J Dermatol; 2023 Feb; 50(2):195-202. PubMed ID: 36514850
[TBL] [Abstract][Full Text] [Related]
7. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.
Sano S; Kubo H; Morishima H; Goto R; Zheng R; Nakagawa H
J Dermatol; 2018 May; 45(5):529-539. PubMed ID: 29569397
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J).
Okubo Y; Mabuchi T; Iwatsuki K; Elmaraghy H; Torisu-Itakura H; Morisaki Y; Nakajo K
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):325-332. PubMed ID: 30317671
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2).
Gordon KB; Warren RB; Gottlieb AB; Blauvelt A; Thaçi D; Leonardi C; Poulin Y; Boehnlein M; Brock F; Ecoffet C; Reich K
Br J Dermatol; 2021 Apr; 184(4):652-662. PubMed ID: 32652544
[TBL] [Abstract][Full Text] [Related]
10. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trial.
Imafuku S; Okubo Y; Tada Y; Ohtsuki M; Colston E; Napoli A; Shao Y; Banerjee S; Morita A
J Dermatol; 2024 Mar; 51(3):365-379. PubMed ID: 38268101
[TBL] [Abstract][Full Text] [Related]
11. Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial.
Warren RB; Lebwohl M; Sofen H; Piguet V; Augustin M; Brock F; C Arendt ; Fierens F; Blauvelt A
J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):2398-2408. PubMed ID: 34192387
[TBL] [Abstract][Full Text] [Related]
12. Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study.
Korge B; Vanhooteghem O; Lynde CW; Machovcova A; Perrussel M; Lazaridou E; Marasca C; Sarro DV; Pousa ID; Fierens F; Williams P; Shimizu S; Heidbrede T; Warren RB
Dermatol Ther (Heidelb); 2024 Jun; ():. PubMed ID: 38937404
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2).
Gisondi P; Gottlieb AB; Elewski B; Augustin M; McBride S; Tsai TF; de la Loge C; Fierens F; López Pinto JM; Tilt N; Lebwohl M
Dermatol Ther (Heidelb); 2023 Jan; 13(1):315-328. PubMed ID: 36509889
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis.
Saeki H; Nakagawa H; Ishii T; Morisaki Y; Aoki T; Berclaz PY; Heffernan M
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1148-55. PubMed ID: 25355284
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension.
Reich K; Ortonne JP; Gottlieb AB; Terpstra IJ; Coteur G; Tasset C; Mease P
Br J Dermatol; 2012 Jul; 167(1):180-90. PubMed ID: 22413944
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.
Imafuku S; Honma M; Okubo Y; Komine M; Ohtsuki M; Morita A; Seko N; Kawashima N; Ito S; Shima T; Nakagawa H
J Dermatol; 2016 Sep; 43(9):1011-7. PubMed ID: 26919410
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies.
Blauvelt A; Paul C; van de Kerkhof P; Warren RB; Gottlieb AB; Langley RG; Brock F; Arendt C; Boehnlein M; Lebwohl M; Reich K
Br J Dermatol; 2021 Apr; 184(4):640-651. PubMed ID: 32531798
[TBL] [Abstract][Full Text] [Related]
19. PGA×BSA: A Measure of Psoriasis Severity Tested in Patients with Active Psoriatic Arthritis and Treated with Certolizumab Pegol.
Walsh JA; Arledge T; Nurminen T; Peterson L; Stark J
J Rheumatol; 2018 Jul; 45(7):922-928. PubMed ID: 29717036
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab treatment in Japanese patients with generalized pustular psoriasis: Results of an open-label phase 3 study.
Morita A; Yamazaki F; Matsuyama T; Takahashi K; Arai S; Asahina A; Imafuku S; Nakagawa H; Hasegawa Y; Williams D; Matsuda N; Kitamura S
J Dermatol; 2018 Dec; 45(12):1371-1380. PubMed ID: 30302793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
